Nektar Therapeutics (NKTR) Expected to Announce Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.5824) per share and revenue of $10.6910 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.91. Nektar Therapeutics had a negative net margin of 297.07% and a negative return on equity of 380.32%. The business had revenue of $21.81 million during the quarter, compared to the consensus estimate of $10.44 million. On average, analysts expect Nektar Therapeutics to post $-10 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Nektar Therapeutics Stock Up 2.3%

Shares of NASDAQ NKTR traded up $1.97 on Wednesday, reaching $86.13. 159,234 shares of the company’s stock traded hands, compared to its average volume of 1,109,156. Nektar Therapeutics has a 12 month low of $7.99 and a 12 month high of $109.00. The business’s 50 day simple moving average is $76.85 and its two-hundred day simple moving average is $60.57. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -8.44 and a beta of 1.24.

Insider Buying and Selling at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the transaction, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This trade represents a 0.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Nektar Therapeutics

Several institutional investors have recently modified their holdings of NKTR. AQR Capital Management LLC grew its stake in shares of Nektar Therapeutics by 336.9% during the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after purchasing an additional 2,807,595 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Nektar Therapeutics in the first quarter valued at approximately $68,000. Rhumbline Advisers raised its holdings in Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 41,948 shares during the period. Marshall Wace LLP purchased a new position in Nektar Therapeutics in the second quarter valued at approximately $367,000. Finally, Headlands Technologies LLC purchased a new position in Nektar Therapeutics in the second quarter valued at approximately $65,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NKTR. HC Wainwright raised their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Citigroup raised their target price on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. TD Cowen assumed coverage on shares of Nektar Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating for the company. Wedbush raised their price target on shares of Nektar Therapeutics from $70.00 to $95.00 and gave the company a “neutral” rating in a research report on Tuesday, April 21st. Finally, B. Riley Financial reissued a “buy” rating and set a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $140.63.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.